– USA, CA – Rezolute, Inc. (NASDAQ: RZLT), today announced the appointments of Dr. Vlad Hogenhuis, M.D., MBA, and Dr. Nerissa Kreher, M.D., M.S., MBA to its Board of Directors.
“We are delighted to welcome rare disease experts Dr. Hogenhuis and Dr. Kreher to our board of directors,” said CEO, Nevan Elam. “Dr. Hogenhuis’ track record of driving growth, culture change and patient impact across global markets coupled with Dr. Kreher’s extensive biotechnology industry experience in both clinical development for rare disease therapies and medical affairs will prove invaluable as we continue to advance RZ358 through late-stage clinical trials and accelerate the growth of our company.”
About Dr. Vlad Hogenhuis
In addition to his role at Rezolute, Dr. Hogenhuis recently served as COO at Ultragenyx in global commercial operations, business development, and manufacturing of medicines for patients with rare diseases. Previously, Dr. Hogenhuis served as senior vice president and global franchise head of specialty pharmaceuticals at GlaxoSmithKline for six years. Before GSK, he served in leadership positions at Merck in the U.S., China, and Europe for 18 years. He also served as a National Institutes of Health fellow in medical decision making at New England Medical Centre in Boston, and as a naval lieutenant surgeon in the Royal Dutch Navy. Dr. Hogenhuis currently serves on the board of GATT Technologies B.V. and IHP Therapeutics.
Dr. Hogenhuis said, “Rezolute’s targeted therapeutic candidates have great promise for patients with serious metabolic disorders across the globe. The company’s advances in developing a monoclonal antibody designed specifically to address congenital hyperinsulinism and an orally administered plasma kallikrein inhibitor for diabetic macular edema present a truly unique opportunity for me to assist in guiding the team at this pivotal stage.”
He earned his medical degree from the University of Leiden in the Netherlands. He received an MBA from the Wharton School of Business at The University of Pennsylvania, Philadelphia.
About Dr. Nerissa Kreher
Dr. Kreher currently serves as chief medical officer at Entrada Therapeutics, in addition to her new role on Rezolute’s board. Previously, she held the role of chief medical officer at Tiburio Therapeutics and Avrobio. Before these roles, Dr. Kreher held leadership positions at Zafgen, Shire, Enobia, and Genzyme. During her career, she has made significant contributions to several approved therapies including Strensiq, and has contributed to global clinical and regulatory strategies for multiple development programs.
Dr. Kreher said, “I am especially excited to join the board at this point in Rezolute’s evolution and look forward to leveraging my experience to provide strategic support to the company as it continues to grow. I am eager to work with their experienced, ambitious team towards a common vision of advancing targeted therapies for rare, metabolic, and life-threatening diseases with transformative potential for patients.”
Dr. Kreher is a board-certified pediatric endocrinologist and holds multiple degrees including her B.S. in biology from the University of North Carolina at Chapel Hill, M.D. from East Carolina University, an M.S. in clinical research from Indiana University-Purdue University Indianapolis, and an MBA from Northeastern University Graduate School of Business Administration.
About Rezolute, Inc.
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead product candidate, RZ358, is in Phase 2b development as a potential treatment for congenital hyperinsulinism, a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an orally available plasma kallikrein inhibitor in Phase 1 development as a potential treatment for diabetic macular edema.
For more information: https://www.rezolutebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
